Breakthrough in Chronic Rhinosinusitis: Lyra's Phase 3 Trial Achieves Statistical Significance, FDA Path Ahead

stocktitan.net/news/LYRA/lyra-therapeutics-reports-positive-results-from-the-enlighten-2-jlamy2v6qyoz.html

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
- Met primary endpoint with statistically significant improvement…

This story appeared on stocktitan.net, 2025-06-02 15:23:16.193000.
The Entire Business World on a Single Page. Free to Use →